The global gene fusion testing market is gaining strong momentum as precision medicine and targeted oncology therapies continue to reshape modern healthcare. Gene fusion testing plays a critical role in identifying chromosomal rearrangements that drive cancer development, enabling clinicians to select personalized treatment strategies. The growing burden of cancer worldwide, coupled with advances in next-generation sequencing (NGS), polymerase chain reaction (PCR), and fluorescence in situ hybridization (FISH), has significantly increased the adoption of gene fusion diagnostics. Additionally, the rising focus on early and accurate diagnosis, companion diagnostics, and biomarker-driven drug development has positioned gene fusion testing as an indispensable component of molecular pathology and oncology workflows.

Access key findings and insights from our Report in this sample – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86836

Market Size and Growth

In 2024, the global gene fusion testing market was valued at approximately US$ 0.7 billion. Over the forecast period, the market is expected to experience robust growth, reaching nearly US$ 2.5 billion by 2035. This expansion reflects a strong compound annual growth rate (CAGR) of 12.1% from 2025 to 2035. The growth trajectory is fueled by increasing investments in genomics research, the expanding clinical utility of fusion gene detection across multiple cancer types, and the rapid integration of advanced diagnostic platforms in hospitals and reference laboratories. Furthermore, regulatory support for molecular diagnostics and the growing pipeline of targeted cancer therapies are expected to sustain long-term market growth.

Market Segmentation

The gene fusion testing market can be segmented based on technology, application, end user, and sample type. By technology, NGS-based testing dominates the market due to its high sensitivity, multiplexing capability, and ability to detect novel gene fusions. PCR and FISH continue to hold relevance, particularly in settings requiring rapid and cost-effective testing. In terms of application, oncology represents the largest segment, with lung cancer, leukemia, lymphoma, and solid tumors being key focus areas. End users include hospitals, diagnostic laboratories, research institutes, and pharmaceutical companies, with diagnostic laboratories accounting for a significant share due to increasing test volumes and outsourcing trends.

Regional Analysis

Regionally, North America leads the global gene fusion testing market, supported by advanced healthcare infrastructure, high awareness of precision medicine, and strong presence of leading diagnostic companies. Europe follows closely, driven by expanding cancer screening programs and supportive regulatory frameworks. The Asia-Pacific region is anticipated to witness the fastest growth over the forecast period, owing to rising healthcare expenditure, improving diagnostic capabilities, and growing adoption of molecular testing in emerging economies. Latin America and the Middle East & Africa are also expected to show steady growth as access to advanced diagnostics gradually improves.

Competitive Landscape

The competitive landscape of the gene fusion testing market is characterized by the presence of established diagnostics and life sciences companies focusing on innovation, partnerships, and portfolio expansion. Key players operating in this market include Amoy Diagnostics Co., Ltd., ArcherDX, Biocartis, Biocare Medical, LLC, F. Hoffmann-La Roche Ltd., Guardant Health, Inc, Illumina, Inc., Myriad Genetics, Inc., Natera, Inc., NeoGenomics, Inc., QIAGEN N.V., and Thermo Fisher Scientific Inc.. These companies compete on technological innovation, test accuracy, turnaround time, and global distribution networks.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.

CORPORATE HEADQUARTER DOWNTOWN,

1000 N. West Street,

Suite 1200, Wilmington, Delaware 19801 USA

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453